Lumida
/RNAC
⌘K
Cartesian Therapeutics Inc

Cartesian Therapeutics Inc

RNAC
$10.38USD+3.18%+0.32 today

MARKET CAP

314.1M

P/E (TTM)

FWD P/E

DAY RANGE

$10 – $11

52W RANGE

$6
$11

AI Summary

Stalk
StalkMedium

In Stage 2 advancing, medium-term bullish structure remains intact with higher highs and rising EMAs, but terminal blow-off top and exhaustion patterns combined with overbought readings call for caution. Price is extended and requires a pullback into the rising EMAs or prior breakout zone for a favorable entry. Long-term downtrend persists as a structural headwind.

  • Strong momentum factor indicates renewed investor traction.
  • Zacks upgraded to hold with $32.60 average target.
  • Deep negative earnings yield and weak profitability factors signal cash burn.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$26.0M$38.9M$2.8M
YoY %+49.6%-92.8%
P / Sales3.9x8.0x67.0x
EV / Sales18.1x13.9x173.3x
Gross Profit, Adj.$26.0M$38.9M$2.8M
YoY %+49.6%-92.8%
Margin %100.0%100.0%100.0%
EV / Gross Profit18.1x13.9x173.3x
EBITDA, Adj.$-84.9M$-35.2M$-83.7M
YoY %+58.6%-138.1%
Margin %-326.3%-90.4%-2994.1%
EV / EBITDA-5.5x-15.4x-5.8x
EBIT$-86.4M$-43.9M$-143.4M
YoY %+49.2%-226.7%
Margin %-332.3%-112.8%-5127.1%
EV / EBIT-5.4x-12.3x-3.4x
Net Income$-257.3M$-77.4M$-130.3M
YoY %+69.9%-68.3%
Net Margin-989.3%-199.0%-4658.6%
EPS (GAAP)-$49.76-$4.49-$5.02
YoY %+91.0%-11.8%